A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu  rin therapy of superficial XXXX .

@entity1 @entity1377 @entity137 @entity2735 @entity5 @entity150 @entity3833
Between August 1981 and July 1984, 93 @entity1 with polychronotopic superficial @entity1377 (Ta and/or T1), flat @entity2735 (Tis), or concomitant superficial papillary and in situ @entity150 were entered into a prospective randomized trial of maintenance v nonmaintenance intravesical bacillus Calmette-Gu  rin (BCG) therapy. Forty-six @entity1 who received BCG weekly for 6 weeks were compared with 47 @entity1 receiving the six-weekly doses of BCG plus monthly BCG for 2 years. Both groups were evaluated every 3 months by cytology, cystoscopy, and biopsy. A significant reduction in the number of recurrent @entity5 per @entity1 -month was demonstrated for both groups (P less than .0001); however, the difference in @entity5 between the two groups was not significant. Additionally, @entity1 receiving maintenance and nonmaintenance therapy had similar @entity5 recurrence and progression rates. These results indicate that monthly maintenance BCG does not prevent, delay, or reduce @entity5 recurrence or progression observed with the 6-week regimen. Maintenance BCG was associated with increased local @entity137 , primarily @entity3833 , frequency, and urgency. Dosage reduction was required in 22 of 47 @entity1 (46.8%). When the data were subjected to multivariate analysis, the presence or absence of @entity5 following induction BCG and PPD skin test results were found to be significant variables. Controlling for either the presence or absence of @entity5 following induction BCG, @entity5 recurrence and progression rates were not significantly different for the two treatment groups. However, the absence of @entity5 after induction BCG was associated with a longer disease-free duration (P = .00001) and time to progression (P = .095). @entity1 with a reactive tuberculin skin test before and after induction BCG had significantly less @entity5 recurrences than @entity1 with different PPD skin tests results (P = .02). @entity5 progression was not related to tuberculin skin testing.
